Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity

AIDS

Volumn 14, Issue 17, 2000, Pages 2679-2686

  Cavaleiro, Rita ^a   Sousa, Ana E ^a   Loureiro, Ana ^a   Victorino, Rui M M ^a,b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

CD40L; HIV envelope proteins; HIV 1; HIV 2; OX40

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 105; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 39; IMMUNOSUPPRESSIVE AGENT; PROTEIN OX40; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIGENS, CD27; ANTIGENS, CD28; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; DNA; FLOW CYTOMETRY; GENE PRODUCTS, ENV; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HIV-2; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MONOCYTES; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034492881     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012010-00007     Document Type: Article

References (43)

1. Lessons from the second AIDS virus, HIV-2
2. Distinct alterations in the distribution of CD45RO+ T-cell subsets in HIV-2 compared with HIV-1 infection
3. Analysis of lymphocyte cell death and apoptosis in HIV-2-infected patients
4. HIV-2 and T cell recognition
5. Reduced rate of disease development after HIV-2 infection as compared to HIV-1
6. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection
7. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
8. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
9. Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein GP120 of human immunodeficiency virus
10. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
11. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production
12. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope
13. Envelope glycoproteins of human immunodeficiency virus type 1: Profound influences on immune functions
14. The production of beta-chemokines induced by HIV-2 envelope glycoprotein
15. Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells
16. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production
17. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein
18. CD40 and CD154 in cell-mediated immunity
19. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
20. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection
21. Ongoing HIV dissemination during HAART
22. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages
23. Host factors in the pathogenesis of HIV disease
24. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies
25. Activation of virus replication after vaccination of HIV-1-infected individuals
26. Immune activation in the context of HIV infection
27. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden
28. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
29. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)
30. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2
31. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: Correlation of t cell apoptosis with beta2 microglobulin concentration and disease evolution
32. How immune-based interventions can change HIV therapy
33. Hydroxyurea and HIV: 5 Years later-from antiviral to immune-modulating effects
34. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys
35. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
36. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease
37. The CD40 pathway in allograft rejection, acceptance, and tolerance
38. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis
39. Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS
40. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: Possible implications for lymphocyte traffic and functional recovery
41. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma
42. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B
43. Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals